FI971420L - Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä - Google Patents

Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä Download PDF

Info

Publication number
FI971420L
FI971420L FI971420A FI971420A FI971420L FI 971420 L FI971420 L FI 971420L FI 971420 A FI971420 A FI 971420A FI 971420 A FI971420 A FI 971420A FI 971420 L FI971420 L FI 971420L
Authority
FI
Finland
Prior art keywords
kgf
diabetes mellitus
treating diabetes
treating
mellitus
Prior art date
Application number
FI971420A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI971420A7 (fi
FI971420A0 (fi
Inventor
Sharon Lea Aukerman
Glenn Frencis Pierce
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FI971420A7 publication Critical patent/FI971420A7/fi
Publication of FI971420A0 publication Critical patent/FI971420A0/fi
Publication of FI971420L publication Critical patent/FI971420L/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI971420A 1994-10-13 1995-10-12 Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä FI971420L (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32334094A 1994-10-13 1994-10-13
US32347594A 1994-10-13 1994-10-13
US48782595A 1995-06-07 1995-06-07
PCT/IB1995/000992 WO1996011950A1 (en) 1994-10-13 1995-10-12 Method of treating diabetes mellitus using kgf

Publications (3)

Publication Number Publication Date
FI971420A7 FI971420A7 (fi) 1997-04-04
FI971420A0 FI971420A0 (fi) 1997-04-04
FI971420L true FI971420L (fi) 1997-04-04

Family

ID=27406268

Family Applications (2)

Application Number Title Priority Date Filing Date
FI971420A FI971420L (fi) 1994-10-13 1995-10-12 Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
FI971536A FI120040B (fi) 1994-10-13 1997-04-11 Keratinosyytti-kasvutekijän analogeja

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI971536A FI120040B (fi) 1994-10-13 1997-04-11 Keratinosyytti-kasvutekijän analogeja

Country Status (23)

Country Link
EP (2) EP0804479B1 (cs)
JP (2) JP4426646B2 (cs)
KR (1) KR100278597B1 (cs)
CN (1) CN1168678A (cs)
AT (2) ATE237633T1 (cs)
AU (1) AU3707795A (cs)
BG (2) BG101392A (cs)
BR (2) BR9509329A (cs)
CA (2) CA2202075C (cs)
CZ (3) CZ98197A3 (cs)
DE (2) DE69530403T2 (cs)
DK (2) DK0785948T3 (cs)
EE (2) EE03975B1 (cs)
ES (2) ES2273338T3 (cs)
FI (2) FI971420L (cs)
HU (2) HU226168B1 (cs)
NO (2) NO318761B1 (cs)
NZ (2) NZ505502A (cs)
PL (2) PL182888B1 (cs)
PT (2) PT785948E (cs)
SI (2) SI0785948T1 (cs)
SK (2) SK43197A3 (cs)
WO (2) WO1996011950A1 (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU647732B2 (en) 1989-01-31 1994-03-31 Stuart A. Aaronson DNA encoding a growth factor specific for epithelial cells
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
WO1995001434A1 (en) 1993-06-29 1995-01-12 Chiron Corporation A truncated keratinocyte growth factor (kgf) having increased biological activity
DE122006000019I1 (de) * 1994-10-13 2006-06-29 Amgen Inc Methode zur reinigung von Keratinocyten-Wachstumsfaktoren
US6077692A (en) * 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
WO1996034017A1 (en) * 1995-04-27 1996-10-31 Coöperatie Suiker Unie U.A. Inulin derivatives
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
WO1998016642A1 (en) * 1996-10-15 1998-04-23 Amgen Inc. Keratinocyte growth factor-2 products
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
US6238888B1 (en) 1997-12-22 2001-05-29 Human Genone Sciences, Inc. Keratinocyte growth factor-2 formulations
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
BR0008759B1 (pt) * 1999-01-14 2014-03-11 Bolder Biotechnology Inc Métodos para a produção de proteinas contendo resíduos de cisteina livre
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
RU2003125643A (ru) * 2001-02-06 2005-01-20 Мерк Патент ГмбХ (DE) Модифицированный фактор роста кератиноцита (kgf) с уменьшенной иммуногенностью
WO2003016505A2 (en) * 2001-08-21 2003-02-27 Chiron Corporation Kgf polypeptide compositions
AU2007214362B2 (en) * 2001-08-21 2009-11-26 Novartis Vaccines And Diagnostics, Inc. KGF polypeptide compositions
RS53548B1 (sr) 2004-12-15 2015-02-27 Swedish Orphan Biovitrum Ab (Publ) Terapeutske formulacije faktora rasta keratinocita
CN102242124B (zh) * 2010-05-10 2013-05-22 齐鲁制药有限公司 改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) * 2020-08-28 2022-09-05 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd ｒｅｇ蛋白質
US5145225A (en) * 1988-07-27 1992-09-08 Muller George M Carpet stretcher
AU647732B2 (en) * 1989-01-31 1994-03-31 Stuart A. Aaronson DNA encoding a growth factor specific for epithelial cells
JP3303211B2 (ja) * 1991-04-26 2002-07-15 武田薬品工業株式会社 ｂＦＧＦムテインおよびその製造法
RU2146148C1 (ru) * 1993-03-26 2000-03-10 Амген Инк. Терапевтическое применение фактора роста кератиноцитов (фрк)
WO1995001434A1 (en) * 1993-06-29 1995-01-12 Chiron Corporation A truncated keratinocyte growth factor (kgf) having increased biological activity
US5348563A (en) * 1993-06-29 1994-09-20 Honeywell Inc. Air purifying apparatus
GB9315501D0 (en) * 1993-07-27 1993-09-08 Ici Plc Surfactant compositions
JPH09503751A (ja) * 1993-08-02 1997-04-15 プリズム ファーマシュティカルズ，インコーポレイティド 細胞毒性抱合体の単一起源性製剤

Also Published As

Publication number Publication date
EP0785948B1 (en) 2003-04-16
JP4426646B2 (ja) 2010-03-03
JP4216329B2 (ja) 2009-01-28
FI971420A7 (fi) 1997-04-04
PL182888B1 (pl) 2002-03-29
FI971536L (fi) 1997-06-09
AU3708395A (en) 1996-05-06
DE69535264D1 (de) 2006-11-23
PT804479E (pt) 2007-02-28
CZ105097A3 (cs) 1998-10-14
KR100278597B1 (ko) 2001-01-15
NO971566D0 (no) 1997-04-04
SK43197A3 (en) 1999-03-12
PT785948E (pt) 2003-09-30
EP0804479A1 (en) 1997-11-05
CA2201940A1 (en) 1996-04-25
NO318761B1 (no) 2005-05-02
JPH10507193A (ja) 1998-07-14
NZ505502A (en) 2005-01-28
BR9509329A (pt) 1997-10-14
NO971568D0 (no) 1997-04-04
BR9509269A (pt) 1997-12-23
ATE342278T1 (de) 2006-11-15
BG63167B1 (bg) 2001-05-31
PL319784A1 (en) 1997-08-18
CA2202075C (en) 2003-12-09
EE9700081A (et) 1997-10-15
CZ297329B6 (cs) 2006-11-15
AU681546B2 (en) 1997-08-28
FI120040B (fi) 2009-06-15
ATE237633T1 (de) 2003-05-15
FI971536A0 (fi) 1997-04-11
DE69530403D1 (de) 2003-05-22
WO1996011950A1 (en) 1996-04-25
PL320484A1 (en) 1997-09-29
SK284534B6 (sk) 2005-06-02
CN1168678A (zh) 1997-12-24
ES2196082T3 (es) 2003-12-16
JPH10507080A (ja) 1998-07-14
NO971568L (no) 1997-06-12
EP0785948A1 (en) 1997-07-30
EE9700225A (et) 1998-02-16
SK45597A3 (en) 1999-02-11
CA2202075A1 (en) 1996-04-25
DE69530403T2 (de) 2003-10-30
ES2273338T3 (es) 2007-05-01
FI971420A0 (fi) 1997-04-04
DK0804479T3 (da) 2007-01-29
BG101392A (en) 1997-10-31
CA2201940C (en) 2009-05-12
HUT78058A (hu) 1999-07-28
CZ98197A3 (cs) 1998-11-11
AU3707795A (en) 1996-05-06
SI0785948T1 (en) 2003-08-31
DK0785948T3 (da) 2003-08-04
CZ297328B6 (cs) 2006-11-15
WO1996011949A2 (en) 1996-04-25
HUT78050A (hu) 1999-07-28
BG101408A (bg) 1997-12-30
EP0804479B1 (en) 2006-10-11
HU226168B1 (en) 2008-05-28
NZ335109A (en) 2000-08-25
DE69535264T2 (de) 2007-02-01
SI0804479T1 (sl) 2006-12-31
WO1996011949A3 (en) 1996-12-12
NO971566L (no) 1997-04-14
EE03975B1 (et) 2003-02-17

Similar Documents

Publication Publication Date Title
FI971420L (fi) Menetelmä diabetes mellituksen hoitamiseksi KGF:ää käyttämällä
IL122718A0 (en) Methods for treating diabetes
PL320937A1 (en) Substituted azetidin-2-ones for treating arterial atheromatosis
FI944955A7 (fi) Menetelmä selluloosa-alustojen lujittamiseksi
IL133643A0 (en) Therapeutic method for management of diabetes mellitus
FI940374A7 (fi) Menetelmä väriaineiden virittämiseksi
FI950699L (fi) Menetelmä insuliinin saamiseksi, jossa on oikein sitoutuneet kystiinisillat
FI941866L (fi) Menetelmä liuoksen fraktioimiseksi
FI971568A7 (fi) Menetelmä resistenttien kasvainten hoitamiseksi
HUP9601189A2 (en) Loading mechanism, as well as, method for using same
AU4017395A (en) Method for treating anxiety
ZA958608B (en) Method of treating diabetes mellitus using kgf
FI20050181L (fi) Menetelmä valmistaa 21-kloorikortikosteroideja
FI971264L (fi) Menetelmä 2,6-di-isopropyylifenolin puhdistamiseksi
FI964428A7 (fi) Menetelmä orgaanisia ainesosia sisältävän väliaineen käsittelemiseksi
FI964001L (fi) Menetelmä 7-trialkyylisilyylibakkatiini III:n valmistamiseksi
FI944583L (fi) Menetelmä hissin käynnistämiseksi
FI954123L (fi) Menetelmä glukoosirepression suppressoimiseksi
FI963018L (fi) Menetelmä gammapyronien valmistamiseksi
IL125762A0 (en) Method for treating heart failure
FI971922L (fi) Menetelmä selluloosan talteenottamiseksi
FI964410L (fi) Menetelmä 4-amino-delta4-3-ketosteroidien valmistamiseksi 4-nitro-delta4-3-ketosteroidien kautta
FI955856A0 (fi) Menetelmä sokereiden dekarbonyloimiseksi
AU4017195A (en) Method for treating anxiety
FI964002A7 (fi) Menetelmä 7-hydroksitaksaanien valmistamiseksi